• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • The Hatter Cardiovascular Institute Horizon Meetings
    • The 19th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2022 – London
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2022
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2022
    • Multiple Sclerosis Nurses at the Limits 2022
    • Previous events
      • Multiple Sclerosis at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor David Baker

Following completing a BSc in Zoology in 1983, he performed post-graduate studies at the Royal College of Surgeons of England on immune tolerance and delayed hypersensitivity responses in the skin and obtained a PhD in 1987. Following the award of Angela Limerick Lectureship to study multiple sclerosis (MS), he turned his attention to delayed hypersensitivity responses in the brain. He developed a novel relapsing model of multiple sclerosis. Although his interests have varied over time, his focus has been on control of neuroimmunological disease and its translational relevance to MS and has published over 200 peer-reviewed papers.

 

His early career focused on genetics; T cell biology, neuroimmunology and blood brain barrier function to name a few examples. In 1994 he became the first ever recipient of a Multiple Sclerosis Society UK Senior fellowship and moved to the Institute of Ophthalmology to develop ocular models of central nervous system autoimmunity. There his group uncovered the first experimental evidence for symptomatic benefit of cannabis and cannabinoids in the control of spasticity. This work led to the development of cannabis-based licensed medicines for treatment of spasticity in MS. His research has focussed development of agents to treat symptoms and promote neuroprotection. He moved to the Institute of Neurology, University College London in 1999 to continue his work on spasticity. He founded a University spin-out company in 2005 to develop his intellectual property. The drug recently completed phase II studies in MS, with results expected in 2017. Having become adept at controlling the peripheral immune response, he used this knowledge to 3Rs “refined” EAE models and created secondary progressive MS models to target studies towards neuroprotection. In 2006 he teamed up with Professor Gavin Giovannoni and moved to Queen Mary University of London, to lead the pre-clinical part of a translational neuroscience team. In addition to trials on symptom control, the team have recently translated some neuroprotection studies from animals into human. The team have also embraced public engagement of science to run a MS research blog (www.ms-res.org).

« Professor David Lomas
Professor Dr med. H. Wiendl »

The 19th Malvern Diabetic Foot Conference
Wednesday, 11 - Friday, 13 May 2022, Malvern, UK

Cell Therapy at the Limits 2022
Monday, 27 & Tuesday, 28 June 2022, London, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 16 & Saturday, 17 September 2022, London, UK

Multiple Sclerosis at the Limits
Monday, 19 & Tuesday, 20 September 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits Japan
Saturday 15th & Sunday 16th October 2022, Tokyo, Japan

Cardiology, Diabetes & Nephrology at the Limits Canada
Q3 2022, Toronto, Canada

Cardiology, Diabetes & Nephrology at the Limits Brazil
April & October 2022, Brazil

The Hatter Cardiovascular Institute Horizon GP Meeting
Wednesday, 9 November 2022
London, UK

The Hatter Cardiovascular Institute Horizon Meeting
Wednesday, 23 November 2022, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2023
London,UK

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2022 At the Limits Ltd.
This site uses cookies More info